A Dose Escalation and Expansion Trial With BYON4228 Alone and in Combination in Patients With Advanced or Metastatic Solid Tumors
- Conditions
- Solid Tumor
- Interventions
- Combination Product: Pembrolizumab
- First Posted Date
- 2025-04-17
- Last Posted Date
- 2025-04-22
- Lead Sponsor
- Byondis B.V.
- Target Recruit Count
- 85
- Registration Number
- NCT06932952
Safety, Pharmacokinetics, and Preliminary Efficacy of BYON4413 in Acute Myeloid Leukemia and Myelodysplastic Neoplasms.
- Conditions
- Relapsed / Refractory MDSRelapsed / Refractory AML
- Interventions
- First Posted Date
- 2024-04-11
- Last Posted Date
- 2025-02-06
- Lead Sponsor
- Byondis B.V.
- Target Recruit Count
- 100
- Registration Number
- NCT06359002
- Locations
- 🇧🇪
Het Ziekenhuisnetwerk Antwerpen, Antwerpen, Belgium
🇧🇪UZ Leuven, Leuven, Belgium
🇳🇱Universitair Medisch Centrum Groningen, Groningen, Netherlands
First-in-human Dose Escalation and Expansion Study With the SIRPα-directed Monoclonal Antibody BYON4228
- Conditions
- Lymphoma
- Interventions
- Drug: BYON4228 + Rituximab
- First Posted Date
- 2023-02-21
- Last Posted Date
- 2025-03-11
- Lead Sponsor
- Byondis B.V.
- Target Recruit Count
- 100
- Registration Number
- NCT05737628
- Locations
- 🇮🇹
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRCCS IRST, Ravenna, Italy
🇮🇹ASST Spedali Civili di Brescia, Brescia, Italy
🇮🇹Istituto di Candiolo - Fondazione del Piemonte per l'Oncologia - IRCCS, Candiolo, Italy
A First-in-human Dose-escalation and Expansion Study With the Antibody-drug Conjugate BYON3521
- First Posted Date
- 2022-04-12
- Last Posted Date
- 2024-06-07
- Lead Sponsor
- Byondis B.V.
- Target Recruit Count
- 31
- Registration Number
- NCT05323045
- Locations
- 🇮🇹
Istituto Europeo di Oncologia, Milan, Italy
🇧🇪Institut Jules Bordet, Brussels, Belgium
🇳🇱Radboud, Nijmegen, Netherlands
Evaluation of Safety and Efficacy of Sodium Thiosulfate (BYON5667) Eye Drops to Reduce Ocular Toxicity in Cancer Patients Treated With SYD985
- Conditions
- Metastatic Breast Cancer
- Interventions
- Drug: BYON5667 & SYD985Drug: Placebo & SYD985
- First Posted Date
- 2021-07-30
- Last Posted Date
- 2024-01-05
- Lead Sponsor
- Byondis B.V.
- Target Recruit Count
- 48
- Registration Number
- NCT04983238
- Locations
- 🇧🇪
University Hospital Antwerp, Antwerp, Belgium
🇧🇪UZ Leuven, Leuven, Belgium
🇪🇸Vall d' Hebron, Barcelona, Spain
Phase I Study of SYD985 With Niraparib in Patients With Solid Tumors
- First Posted Date
- 2020-01-21
- Last Posted Date
- 2024-01-05
- Lead Sponsor
- Byondis B.V.
- Target Recruit Count
- 32
- Registration Number
- NCT04235101
- Locations
- 🇧🇪
University Hospital Antwerp, BE, Antwerp, Belgium
🇳🇱Radboud University Medical Center/ NL, Nijmegen, Netherlands
🇬🇧The Christie NHS Foundation Trust/ UK, Manchester, United Kingdom
SYD985 in Patients With HER2-expressing Recurrent, Advanced or Metastatic Endometrial Carcinoma
- First Posted Date
- 2019-12-19
- Last Posted Date
- 2024-05-30
- Lead Sponsor
- Byondis B.V.
- Target Recruit Count
- 64
- Registration Number
- NCT04205630
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
🇰🇷Seoul National University Bundang Hospital, Seongnam-si, Korea, Republic of
🇰🇷Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of
A First-in-human Dose-escalation and Expansion Study With the Antibody-drug Conjugate SYD1875
- First Posted Date
- 2019-12-17
- Last Posted Date
- 2023-01-30
- Lead Sponsor
- Byondis B.V.
- Target Recruit Count
- 31
- Registration Number
- NCT04202705
- Locations
- 🇫🇷
Institut Bergonié, Bordeaux, France
🇧🇪Institut Jules Bordet, Brussels, Belgium
🇫🇷Centre Oscar Lambret, Lille, France
SYD985 vs. Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer
- Conditions
- Metastatic Breast Cancer
- Interventions
- Drug: (vic-)trastuzumab duocarmazineDrug: Physician's choice
- First Posted Date
- 2017-08-25
- Last Posted Date
- 2023-10-19
- Lead Sponsor
- Byondis B.V.
- Target Recruit Count
- 437
- Registration Number
- NCT03262935
- Locations
- 🇧🇪
CHU Liege, Liege, Belgium
🇬🇧Velindre Cancer Centre VCC, Cardiff, United Kingdom
🇬🇧The Royal Marsden NHS Foundation Trust, London, United Kingdom
First-in-human Study With the Antibody-drug Conjugate SYD985 to Evaluate Safety and Efficacy in Cancer Patients
- Conditions
- Solid Tumors
- Interventions
- Drug: SYD985 (trastuzumab vc-seco-DUBA)
- First Posted Date
- 2014-10-29
- Last Posted Date
- 2023-08-14
- Lead Sponsor
- Byondis B.V.
- Target Recruit Count
- 185
- Registration Number
- NCT02277717
- Locations
- 🇪🇸
Institut Catala d'Oncologia, Barcelona, Spain
🇳🇱UMC, Rotterdam, Netherlands
🇧🇪Institut Jules Bordet, Brussels, Belgium